Mainz Biomed B.V. (MYNZ) AI Stock Analysis

• Market Cap: $11.24M
• Dividend Yield: N/A
• Average Volume (3M): 230.18K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.06
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 19
• Sector: Healthcare
• Sector Strength: 70
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -65.57
• Shares Outstanding: 3,038,853
• 10 Day Avg. Volume: 421,395
• 30 Day Avg. Volume: 230,176
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• Price to Cash Flow (P/CF): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $14.00
• Price Target Upside: 293.26% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

Mainz Biomed B.V. faces significant financial and technical challenges, with negative earnings and bearish technical indicators. The lack of profitability and high leverage are major concerns, and the current valuation does not offer a compelling case for investment. Strategic improvements in financial performance and technical indicators are needed to enhance the stock's attractiveness.

Positive Factors

Collaborations and Partnerships

An agreement with Quest Diagnostics has been signed for the ReconAAsense study with an option for commercialization.

Market Opportunities

Existing tests with a similar format, such as Cologuard, have achieved commercial success with >$2B in annual sales, providing an opportunity for Mainz Biomed to capture share.

Technological Advancements

Mainz Biomed's Next Generation Test uses mRNA and FIT to enhance detection rates for advanced adenomas, showing improved results compared to industry standards.

Negative Factors

Capital Requirements

The company needs to raise a significant amount of capital to complete the eAArly DETECT 2 and a pivotal study before regulatory submission.

Financial Challenges

Net loss totaled $11.0M in the first half of the year, with revenue being only $0.5M, indicating financial challenges.

Stock Rating Downgrade

Due to the company's current share price and market cap, the analyst believes it is prudent to downgrade the rating from Buy to Neutral without a price target.

Mainz Biomed B.V. Business Overview & Revenue Model

Company Description

Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.

How the Company Makes Money

Mainz Biomed generates revenue through the sale of its proprietary diagnostic tests to healthcare providers, clinics, and laboratories. The company's primary revenue stream is derived from the commercialization of its flagship colorectal cancer screening test. Additionally, Mainz Biomed engages in strategic partnerships and collaborations with research institutions and healthcare organizations to enhance and expand its diagnostic offerings. These partnerships may contribute to revenue through joint development agreements, licensing deals, and the sharing of research findings that support product innovation and market expansion.

Mainz Biomed B.V. Financial Statement Overview

Summary

Mainz Biomed B.V. operates in the Medical Diagnostics & Screening industry and faces considerable financial difficulties. While there is some revenue growth and improvement in gross profit margin, the company is struggling with substantial losses and cash flow issues. The high leverage and low equity base pose additional risks, potentially impacting its financial health and operational sustainability.

Income Statement

Mainz Biomed B.V. has shown some revenue growth over time; however, the company remains unprofitable with negative EBIT and net income consistently. The gross profit margin improved from previous years, but the net profit margin is substantially negative, indicating significant operational challenges.

Balance Sheet

The company's balance sheet shows an improvement in stockholders' equity over the years, yet it remains highly leveraged with a rising debt-to-equity ratio. The equity ratio is very low, reflecting potential risks in financial stability.

Cash Flow

The operating cash flow is persistently negative, and free cash flow has worsened over the years. The company faces significant challenges in generating cash from operations, which indicates potential liquidity issues.

Breakdown
Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
895.48K	529.88K	577.35K	493.56K	281.39K
	Gross Profit
509.66K	182.15K	177.62K	123.08K	-61.27K
	EBIT
-26.64M	-26.17M	-9.38M	-325.81K	-921.91K
	EBITDA
-25.01M	-25.72M	-11.28M	-257.64K	-702.08K
	Net Income Common Stockholders
-26.30M	-26.45M	-12.07M	-886.18K	-1.17M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
7.07M	17.14M	8.73M	122.57K	203.59K
	Total Assets
15.41M	20.24M	10.04M	673.27K	715.96K
	Total Debt
7.42M	3.23M	2.58M	2.98M	2.41M
	Net Debt
349.86K	-13.91M	-6.15M	2.86M	2.21M
	Total Liabilities
12.16M	6.14M	3.68M	3.41M	2.67M
	Stockholders Equity
3.25M	14.10M	6.36M	-2.74M	-1.95M
Cash Flow		Free Cash Flow
-23.84M	-15.43M	-3.24M	-478.42K	-416.50K
	Operating Cash Flow
-21.94M	-14.77M	-3.22M	-468.74K	-416.50K
	Investing Cash Flow
-1.90M	-658.48K	1.20M	-9.69K	0.00
	Financing Cash Flow
14.23M	23.94M	10.61M	396.68K	424.00K

Mainz Biomed B.V. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 3.56
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MYNZ, the sentiment is Negative. The current price of 3.56 is above the 20-day moving average (MA) of 3.29, below the 50-day MA of 4.19, and below the 200-day MA of 8.43, indicating a neutral trend. The MACD of -0.19 indicates Negative momentum. The RSI at 46.20 is Neutral, neither overbought nor oversold. The STOCH value of 38.12 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MYNZ.

Mainz Biomed B.V. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
INBS	53 Neutral	$8.72M	―	-279.80%	―	23.21%	57.43%
Sector *	52 Neutral	$5.38B	3.59	-41.63%	2.87%	17.72%	1.87%
PRPO	44 Neutral	$9.15M	―	-32.35%	―	21.95%	39.43%
BNGO	43 Neutral	$13.49M	―	-170.33%	―	-14.79%	76.94%
MYNZ	42 Neutral	$11.24M	―	-809.29%	―	―	―
BIAF	42 Neutral	$9.86M	―	-242.44%	―	269.68%	17.26%
TRIB	35 Underperform	$8.64M	―	77.20%	―	-3.76%	39.52%